Overall rank by patents
#35,018
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Decipher Biosciences, Inc.
USPTO PatentsView assignee record - 7 granted patents across 7 technology areas, active 2019–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).
7
Total patents granted
7
CPC technology areas
9.7
Avg claims per patent
+500%
5-year filing velocity
The verdict
Decipher holds 7 US patents across 7 technology areas, rank #35,018 of 50,000 tracked assignees.
- #35,018
- of 50,000 US assignees by volume
- Top 84%
- by Innovation Score (25.0/100)
- 9.7
- avg claims per patent
- +500%
- filing velocity, last 5 yrs
Portfolio overview
Decipher Biosciences, Inc. has been granted 7 US utility patents between 2019 and 2024, placing Decipher Biosciences, Inc. at rank #35,018 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 9.7 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Decipher Biosciences, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Decipher sits between Decurtis Llc (7 patents, rank #35,014) and Deeproot Green Infrastruture, Llc (7 patents, rank #35,022) - the closest US assignees by grant volume. The composite Innovation Score of 25.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 1 in the 2015–2019 window, a +500% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Decipher Biosciences, Inc.'s 9.7 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Decipher Biosciences, Inc. against peers pursuing similar technology classes.
Who files at Decipher's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Decurtis
DeCurtis LLC
7 patents
- Dealvector
DealVector, Inc.
7 patents
- Deborah Adler
Deborah Adler LLC
7 patents
- Dechoker
Dechoker LLC
7 patents
- Decra Stone
Decra Stone, Inc.
7 patents
- Deep Casing Tools
Deep Casing Tools Limited
7 patents
- Deep Imaging
Deep Imaging Technologies, Inc.
7 patents
- Deeproot Green In…
DeepRoot Green Infrastruture, LLC
7 patents
- Decipher Bioscien… ◀
Decipher Biosciences, Inc.
7 patents
What this shows Decipher holds 7 patents at rank #35,018, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Decipher
By rank, the assignees closest to #35,018 in granted patent volume.
- Decurtis Llc #35,014 · 7 patents
- Dealvector, Inc. #35,015 · 7 patents
- Deborah Adler Llc #35,016 · 7 patents
- Dechoker Llc #35,017 · 7 patents
- Decra Stone, Inc. #35,019 · 7 patents
- Deep Casing Tools Limited #35,020 · 7 patents
- Deep Imaging Technologies, Inc. #35,021 · 7 patents
- Deeproot Green Infrastruture, Llc #35,022 · 7 patents
Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)
Other assignees with the most granted patents in Decipher's primary technology class.
- The Regents Of The University Of California 581 in class
- Life Technologies Corporation 546 in class
- Illumina, Inc. 445 in class
- President And Fellows Of Harvard College 387 in class
- Immatics Biotechnologies Gmbh 286 in class
- 10x Genomics, Inc. 282 in class
- The Board Of Trustees Of The Leland Stanford Junior University 266 in class
- Pacific Biosciences OF California, Inc. 259 in class
Decipher's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
25 Top 84% higher than 16% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 14.3% |
| 2020 | 1 | 14.3% |
| 2021 | 3 | 42.9% |
| 2022 | 1 | 14.3% |
| 2024 | 1 | 14.3% |
Which technologies does Decipher Biosciences, Inc. patent most?
Top 7 of 7 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Velocity Accelerating
Frequently Asked Questions
How many patents does Decipher Biosciences, Inc. hold?
Decipher Biosciences, Inc. holds 7 US granted patents filed between 2019 and 2024, spanning 7 technology areas.
What is Decipher Biosciences, Inc.'s Innovation Score?
Decipher Biosciences, Inc. has an Innovation Score of 25.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Decipher Biosciences, Inc. focus on?
Decipher Biosciences, Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 7 patents. The company has filed patents in 7 CPC subclasses total.
Is Decipher Biosciences, Inc.'s patent filing rate increasing or decreasing?
Decipher Biosciences, Inc.'s recent filing velocity is +500% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Decipher Biosciences, Inc.'s patents?
Decipher Biosciences, Inc.'s patents average 9.7 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Decipher Biosciences, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Decipher's 7 grants land it in the top 84% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Decipher ranks #35,018 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.